OTCMKTS:PBSV Pharma-Bio Serv Q3 2025 Earnings Results & Report $0.50 0.00 (0.00%) As of 11/11/2026 Pharma-Bio Serv missed analyst expectations on both earnings and revenue in its Q3 2025 results, released September 15, 2025. The company reported EPS of -$0.01 versus the $0.03 consensus estimate, while revenue of $1.96 million fell short of the $3 million estimate by $1.04 million. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2025Report DateSeptember 15, 2025TimeBefore Market Opens Pharma-Bio Serv EPS ResultsActual EPS-$0.01Consensus EPS $0.03Beat/MissMissed by -$0.04One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersPharma-Bio Serv Revenue ResultsActual Revenue$1.96 millionExpected Revenue$3 millionBeat/MissMissed by -$1.04 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Pharma-Bio Serv Q3 2025 Earnings FAQ Did Pharma-Bio Serv beat earnings estimates for Q3 2025? Pharma-Bio Serv (OTCMKTS:PBSV) reported earnings of -$0.01 per share for Q3 2025, missing the consensus estimate of $0.03. The report was announced on Monday, September 15, 2025. What was Pharma-Bio Serv's revenue for Q3 2025? Pharma-Bio Serv reported revenue of $1.96 million for Q3 2025, against a consensus estimate of $3 million. Pharma-Bio Serv Earnings HeadlinesPharma-Bio Serv (PBSV)September 25, 2026 | mx.investing.comPBSV Changes Proving to be Beneficial to BusinessSeptember 15, 2026 | msn.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)PBSV is a Small Stock Worth a LookJune 16, 2026 | finance.yahoo.comPharma-Bio Serv Inc.: Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2026June 15, 2026 | finanznachrichten.dePBSV Showing Improved Operations and Strong DividendMarch 18, 2026 | finance.yahoo.comSee More Pharma-Bio Serv Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharma-Bio Serv? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharma-Bio Serv and other key companies, straight to your email. Email Address About Pharma-Bio ServPharma-Bio Serv (OTCMKTS:PBSV), Inc. is a professional services and consulting company that supports pharmaceutical, biotechnology, medical device, and related life sciences organizations. Its work is focused on helping clients develop, implement, and maintain the technical, quality, and regulatory systems required to manufacture and commercialize healthcare products. The company provides services that may include validation, regulatory compliance, quality assurance, engineering, technical consulting, project management, and support for manufacturing and facility-related initiatives. These services are intended to help clients meet applicable industry standards and regulatory requirements throughout the product and facility life cycles. Pharma-Bio Serv has historically served companies operating in Puerto Rico and other life sciences markets, including the United States. The company’s shares trade under the symbol PBSV on the OTC Markets. Publicly available information about its current leadership and operations is limited.View Pharma-Bio Serv ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
